Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | C3AR1 | Q16581 | 5/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 2/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL517153 | 1.00 | PTGES (0.33) | PTGESSMN1; SMN2C3AR1KMT2AL3MBTL1 | |
| SCHEMBL517327 | 0.91 | PTGES (0.39) | PTGESSMN1; SMN2C3AR1 | |
| SCHEMBL517645 | 0.91 | PTGES (0.39) | PTGESSMN1; SMN2C3AR1 | |
| SCHEMBL517806 | 0.88 | P4HB (0.32) | PTGES | |
| Bicarbonate SCHEMBL16457191 | 0.87 | FAAH (0.34) | PTGESSMN1; SMN2C3AR1KMT2AMEN1 | |
| SCHEMBL517193 | 0.84 | PTGES (0.33) | PTGESSMN1; SMN2C3AR1KMT2AMEN1 | |
| SCHEMBL517807 | 0.84 | PTGES (0.31) | PTGESSMN1; SMN2C3AR1 | |
| SCHEMBL517046 | 0.83 | CYP3A4 (0.36) | KMT2AL3MBTL1 | |
| SCHEMBL517076 | 0.82 | TDP1 (0.43) | PTGESC3AR1 | |
| SCHEMBL1178437 | 0.82 | PTGES (0.45) | PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406215-B1 | OXO-HETEROCYCLICALLY SUBSTITUTED ALKYL CARBOXYLIC ACIDS AND USE THEREOF | BAYER IP GMBH (DE) | 2014-04-16 | — | — | EP | disclosed |
| EP-2406215-B1 | OXO-HETEROCYCLICALLY SUBSTITUTED ALKYL CARBOXYLIC ACIDS AND USE THEREOF | BAYER IP GMBH (DE) | 2014-04-16 | — | — | EP | disclosed |
| US-8642592-B2 | Oxo-heterocyclically substituted alkyl carboxylic acids and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-8642592-B2 | Oxo-heterocyclically substituted alkyl carboxylic acids and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-20120028971-A1 | OXO-HETEROCYCLICALLY SUBSTITUTED ALKYL CARBOXYLIC ACIDS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028971-A1 | OXO-HETEROCYCLICALLY SUBSTITUTED ALKYL CARBOXYLIC ACIDS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028971-A1 | OXO-HETEROCYCLICALLY SUBSTITUTED ALKYL CARBOXYLIC ACIDS AND USE THEREOF | AADAC, OTC, HCAR2 | PTGES 208/4885SMN1; SMN2 3212/4885C3AR1 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.